STOCK TITAN

Capricor Therapeutics (CAPR) Schedule 13G: Suvretta reports 6.6% stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Capricor Therapeutics reports Schedule 13G ownership disclosures showing Suvretta Capital Management, LLC and affiliated parties hold multi‑percent stakes. Suvretta reports 3,417,891 shares (6.6%), Averill Master Fund, Ltd. reports 2,917,420 shares (5.6%), and Aaron Cowen reports 3,417,891 shares (6.6%). The filing states these shares are directly owned by advisory clients of Suvretta Capital Management, and the reported holdings reflect shared voting and dispositive power for the listed reporting persons.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



SUVRETTA CAPITAL MANAGEMENT, LLC
Signature:By: /s/ Andrew Nathanson
Name/Title:Andrew Nathanson,General Counsel and Chief Compliance Officer
Date:02/26/2026
Averill Master Fund, Ltd.
Signature:By: /s/ Andrew Nathanson
Name/Title:Andrew Nathanson, Authorized Signatory
Date:02/26/2026
Aaron Cowen
Signature:By: /s/ Aaron Cowen
Name/Title:Aaron Cowen
Date:02/26/2026

Comments accompanying signature: * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
Exhibit Information

[Exhibit A - Joint Filing Agreement] [Exhibit B - Control Person Identification]

FAQ

What stake does Suvretta Capital hold in Capricor (CAPR)?

Suvretta Capital reports 3,417,891 shares (6.6%) beneficially owned. The filing attributes these shares to advisory clients of Suvretta, and shows shared voting and dispositive power as disclosed in the Schedule 13G dated 02/26/2026.

How many shares does Averill Master Fund report for CAPR?

Averill Master Fund, Ltd. reports 2,917,420 shares (5.6%) beneficially owned. The Schedule 13G lists this holding under shared voting and dispositive power and identifies Averill as an advisory client holding reported by Suvretta.

Does Aaron Cowen personally own the reported CAPR shares?

Aaron Cowen is reported with 3,417,891 shares (6.6%) and shared voting/dispositive power. The filing includes a disclaimer that each reporting person disclaims beneficial ownership except to the extent of pecuniary interest.

Are these CAPR holdings controlled directly by the reporting firms?

The filing states the securities are directly owned by advisory clients of Suvretta Capital Management, with Suvretta and the reporting persons showing shared voting and dispositive power over the listed shares.

When was the Schedule 13G for CAPR signed?

The signatures on the Schedule 13G are dated 02/26/2026. The cover identifies the reporting date for the holdings as 02/19/2026 and includes joint filing and control‑person exhibits.
Capricor Therapeutics Inc

NASDAQ:CAPR

CAPR Rankings

CAPR Latest News

CAPR Latest SEC Filings

CAPR Stock Data

1.52B
44.04M
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO